Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Depreciation and Depletion (2020 - 2025)

Historic Depreciation and Depletion for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $10000.0.

  • Gain Therapeutics' Depreciation and Depletion changed 0.0% to $10000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $39000.0, marking a year-over-year increase of 833.33%. This contributed to the annual value of $38000.0 for FY2024, which is 857.14% up from last year.
  • As of Q3 2025, Gain Therapeutics' Depreciation and Depletion stood at $10000.0, which was down 0.0% from $10000.0 recorded in Q2 2025.
  • Over the past 5 years, Gain Therapeutics' Depreciation and Depletion peaked at $17139.0 during Q2 2023, and registered a low of $2158.0 during Q2 2021.
  • Moreover, its 5-year median value for Depreciation and Depletion was $9000.0 (2023), whereas its average is $8239.7.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first surged by 43308.62% in 2022, then tumbled by 4748.82% in 2024.
  • Over the past 5 years, Gain Therapeutics' Depreciation and Depletion (Quarter) stood at $5785.0 in 2021, then soared by 34.35% to $7772.0 in 2022, then rose by 15.8% to $9000.0 in 2023, then increased by 11.11% to $10000.0 in 2024, then changed by 0.0% to $10000.0 in 2025.
  • Its Depreciation and Depletion was $10000.0 in Q3 2025, compared to $10000.0 in Q2 2025 and $9000.0 in Q1 2025.